journal
https://read.qxmd.com/read/38644723/construction-of-gpc3-modified-lipopolymer-sirna-delivery-system
#1
JOURNAL ARTICLE
Dandan Sun, Xiaoyu Li, Yaru Liu, Jishan Quan, Guangyu Jin
BACKGROUND: Gene therapy has been widely concerned because of its unique therapeutic mechanism. However, due to the lack of safe and effective carries, it has not been widely used in clinical practice. Glypican 3 (GPC3) is a highly specific proteoglycan for hepatocellular carcinoma and is a potential diagnostic and therapeutic target for hepatocellular carcinoma. Herein, to monitor the effect of gene therapy and enhance the transfection efficiency of gene carriers, GPC3-modified lipid polyethyleneimine-modified superparamagnetic nanoparticle (GLPS), a type of visualized carrier for siRNA (small-interfering RNA) targeting the liver, was prepared...
April 19, 2024: Current Pharmaceutical Design
https://read.qxmd.com/read/38644722/nanotechnology-in-orthodontics-unveiling-pain-mechanisms-innovations-and-future-prospects-of-nanomaterials-in-drug-delivery
#2
JOURNAL ARTICLE
Divya Sharma, Shiv Kumar, Yogesh Garg, Shruti Chopra, Amit Bhatia
Orthodontic pain is characterized by sensations of tingling, tooth discomfort, and intolerance. According to the oral health report, over forty percent of children and adolescents have undergone orthodontic treatment. The efficacy of orthodontic treatment involving braces can be compromised by the diverse levels of discomfort and suffering experienced by patients, leading to suboptimal treatment outcomes and reduced patient adherence. Nanotechnology has entered all areas of science and technology. This review provides an overview of nanoscience, its application in orthodontics, the underlying processes of orthodontic pain, effective treatment options, and a summary of recent research in Nano-dentistry...
April 19, 2024: Current Pharmaceutical Design
https://read.qxmd.com/read/38639271/the-impact-of-spironolactone-co-administration-on-cyclosporin-initial-dosage-optimization-for-pediatric-refractory-nephrotic-syndrome
#3
JOURNAL ARTICLE
Huan-Huan Han, Min Rui, Yang Yang, Jia-Fang Cui, Xue-Ting Huang, Shi-Jia Zhang, Su-Mei He, Dong-Dong Wang, Xiao Chen
OBJECTIVES: Cyclosporin has been used for the treatment of pediatric refractory nephrotic syndrome (PRNS). However, the narrow therapeutic window and large pharmacokinetic variability make it difficult to individualize cyclosporin administration. Meanwhile, spironolactone has been reported to affect cyclosporin metabolism in PRNS patients. This study aims to explore the initial dosage optimization of cyclosporin in PRNS based on the impact of spironolactone co-administration. METHODS: Monte Carlo simulation based on a previously established cyclosporin population pharmacokinetic model for PRNS was used to design cyclosporin dosing regimen...
April 18, 2024: Current Pharmaceutical Design
https://read.qxmd.com/read/38638053/the-therapeutic-application-of-hydrogen-in-cancer-the-potential-and-challenges
#4
JOURNAL ARTICLE
Morteza Nazari Khiji, Faezeh Arghidash, Ghazaleh Khalili Tanha, Rasoul Hossein Zadeh, Elnaz Ghorbani, Majid Khazaei, Seyed Mahdi Hassanian, Ibrahim Saeed Gataa, Alfred King-Yin Lam, Elisa Giovannetti, Gordon A Ferns, Elham Nazari, Amir Avan
Hydrogen therapy has emerged as a possible approach for both preventing and treating cancer. Cancers are often associated with oxidative stress and chronic inflammation. Hydrogen, with its unique physiological functions and characteristics, exhibits antioxidant, anti-inflammatory, and anti-apoptotic properties, making it an attractive candidate for cancer treatment. Through its ability to mitigate oxidative damage, modulate inflammatory responses, and sustain cellular viability, hydrogen demonstrates significant potential in preventing cancer recurrence and improving treatment outcomes...
April 17, 2024: Current Pharmaceutical Design
https://read.qxmd.com/read/38638052/recent-advances-in-the-treatment-strategies-of-friedreich-s-ataxia-a-review-of-potential-drug-candidates-and-their-underlying-mechanisms
#5
JOURNAL ARTICLE
Aman Kumar Saini, Neha Anil, Ardra N Vijay, Bharti Mangla, Shamama Javed, Pankaj Kumar, Waquar Ahsan
BACKGROUND: Friedreich's ataxia (FRDA) is a rare hereditary neurodegenerative disorder characterized by progressive ataxia, cardiomyopathy, and diabetes. The disease is caused by a deficiency of frataxin, a mitochondrial protein involved in iron-sulfur cluster synthesis and iron metabolism. OBJECTIVE: This review aims to summarize recent advances in the development of treatment strategies for FRDA, with a focus on potential drug candidates and their mechanisms of action...
April 17, 2024: Current Pharmaceutical Design
https://read.qxmd.com/read/38629355/effect-of-statins-on-serum-levels-of-tnf-alpha-and-interleukin-6-in-patients-with-kidney-disease-a-meta-analysis-of-randomized-clinical-trials
#6
Bahman Razi, Saeed Aslani, Danyal Imani, Sajad Salehiyeh, Mahdieh Fasihi, Ċ½eljko Reiner, Amirhossein Sahebkar
BACKGROUND AND OBJECTIVES: Some clinical trials have indicated the beneficial effects of statins in patients with kidney disease, while others have reported no positive effect of statins in these patients. We conducted this meta-analysis to identify the effects of statins on serum levels of interleukin-6 (IL-6) and Tumor Necrosis Factor Alpha (TNF-α) in patients with kidney disease. DESIGNS AND METHODS: A systematic literature search was performed using PubMed, Scopus, and Web of Science databases to identify all studies published from inception to August, 2022...
April 16, 2024: Current Pharmaceutical Design
https://read.qxmd.com/read/38629357/lipase-and-protease-production-ability-of-multi-drug-resistant-bacteria-worsens-the-outcomes-of-wound-infections
#7
JOURNAL ARTICLE
Attaur Rahman, Saiqa Sardar, Zeeshan Niaz, Asif Khan, Sheheryar, Abdulwahed Fahad Alrefaei, Muhammad Hamayun, Sajid Ali
BACKGROUND: Surgical site infections are one of the major clinical problems in surgical departments that cost hundreds of millions of dollars to healthcare systems around the world. AIM: The study aimed to address the pressing issue of surgical site infections, which pose significant clinical and financial burdens on healthcare systems globally. Recognizing the substantial costs incurred due to these infections, the research has focused on understanding the role of lipase and protease production by multi-drug resistant bacteria isolated from surgical wounds in the development of post-surgical wound infections...
April 15, 2024: Current Pharmaceutical Design
https://read.qxmd.com/read/38629356/network-pharmacology-combined-with-molecular-docking-approach-to-investigate-the-mechanism-of-chushiweiling-decoction-against-perianal-eczema
#8
JOURNAL ARTICLE
Ying Liu, Min Hao, Xinyue Fang, Yifei Qian, Yahui Wang, Shuai Yan
BACKGROUND: ChuShiWeiLing Decoction (CSWLD) is a famous classical Chinese prescription for the treatment of eczema with desirable effect in clinical practice. It has gradually exerted good curative effects on perianal eczema (PE) in recent years, but its specific mechanism is not elucidated yet. OBJECTIVE: This research explores the underlying pharmacological mechanism of CSWLD in addressing PE through network pharmacology combined with molecular docking strategy...
April 15, 2024: Current Pharmaceutical Design
https://read.qxmd.com/read/38623974/preclinical-pharmacokinetics-and-pharmacology-study-of-rc98-a-programmed-cell-death-ligand-1-monoclonal-antibody-in-cynomolgus-monkeys
#9
JOURNAL ARTICLE
Ling Wang, Qiaoning Li, Chenglian Deng, Zhihao Liu, Fang Wang, Shenjun Li, Lihou Dong, Jing Jiang
INTRODUCTION: RC98 is the monoclonal antibody against Programmed Cell Death Ligand 1 (PD-L1). Relevant reports have confirmed that the influence of PD-L1 expressed by tumor cells on antitumor CD8+ T cell responses is well characterized, but the impact of PD-L1 expressed by immune cells has not been well defined. OBJECTIVE: This study aimed to design a Pharmacokinetics/Pharmacology (PK/PD) study of RC98 in normal cynomolgus monkeys to research the effect on the immune system...
April 15, 2024: Current Pharmaceutical Design
https://read.qxmd.com/read/38623973/synthesis-of-rupestonic-acid-l-ephedrine-derivatives-with-preliminary-in-vitro-anti-influenza-viral-activity
#10
JOURNAL ARTICLE
Jianping Yong, Canzhong Lu
BACKGROUND: Influenza virus is a kind of RNA virus. Nowadays, the high incidence of influenza and the morbidity and mortality of epidemic influenza are substantial. It has been reported that one hundred million people in the world are infected with influenza viruses, and two hundred and fifty thousand to five hundred thousand people die from the flu per year. In 2021, the number of infected persons in China was reported to be 654,700, and 0.07% of the infected persons died. The flu has caused a serious threat to human survival...
April 15, 2024: Current Pharmaceutical Design
https://read.qxmd.com/read/38623972/colorectal-cancer-stem-cell-biomarkers-biological-traits-and-prognostic-insights
#11
JOURNAL ARTICLE
Atena Soleimani, Nikoo Saeedi, Abdulridha Mohammed Al-Asady, Elnaz Nazari, Reyhane Hanaie, Majid Khazaei, Elnaz Ghorbani, Hamed Akbarzade, Mikhail Ryzhikov, Amir Avan, Seyed Mahdi Hasanian Mehr
Due to self-renewal, differentiation, and limitless proliferation properties, Cancer Stem Cells (CSCs) increase the probability of tumor development. These cells are identified by using CSC markers, which are highly expressed proteins on the cell surface of CSCs. Recently, the therapeutic application of CSCs as novel biomarkers improved both the prognosis and diagnosis outcome of colorectal Cancer. In the present review, we focused on a specific panel of colorectal CSC markers, including LGR5, ALDH, CD166, CD133, and CD44, which offers a targeted and comprehensive analysis of their functions...
April 15, 2024: Current Pharmaceutical Design
https://read.qxmd.com/read/38623971/evaluating-the-imperative-role-of-pre-and-post-ectd-standards-in-dossier-validation-an-inevitable-outlook
#12
EDITORIAL
Niraj S Patil, Animesh Ranjan, Raj Kumar Narang, Amandeep Singh
No abstract text is available yet for this article.
April 15, 2024: Current Pharmaceutical Design
https://read.qxmd.com/read/38616755/revolutionizing-neurological-disorder-treatment-integrating-innovations-in-pharmaceutical-interventions-and-advanced-therapeutic-technologies
#13
JOURNAL ARTICLE
Rimpi Arora, Ashish Baldi
Neurological disorders impose a significant burden on individuals, leading to disabilities and a reduced quality of life. However, recent years have witnessed remarkable advancements in pharmaceutical interventions aimed at treating these disorders. This review article aims to provide an overview of the latest innovations and breakthroughs in neurological disorder treatment, with a specific focus on key therapeutic areas such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, and stroke...
April 9, 2024: Current Pharmaceutical Design
https://read.qxmd.com/read/38616752/in-vitro-modified-release-studies-on-melatoninergic-fluorinated-phenylalkylamides-circumventing-their-lipophilicity-for-oral-administration
#14
JOURNAL ARTICLE
Marilena Vlachou, Angeliki Siamidi, Chrystalla Protopapa, Michalis Vlachos, Sofia Kloutsou, Chrysoula-Christina Dreliozi, Ioannis P Papanastasiou
INTRODUCTION: In an attempt to circumvent the lipophilicity burden for the oral administration of new potent synthetic melatoninergic fluorine-substituted methoxyphenylalkyl amides, we conducted in vitro modified release studies using carefully selected matrix tablets' biopolymeric materials in different ratios. METHOD: In particular, we sought to attain release profiles of these analogues similar to that of the parent compound, the chronobiotic hormone Melatonin (MLT), and also of the commercially available drug, Circadin®...
April 9, 2024: Current Pharmaceutical Design
https://read.qxmd.com/read/38616754/network-pharmacology-molecular-docking-analysis-and-molecular-dynamics-simulation-of-scutellaria-baicalensis-in-the-treatment-of-liver-fibrosis
#15
JOURNAL ARTICLE
Junrui Wang, Zhuoqing Wu, Xiaolei Chen, Ying Sun, Shuyao Ma, Jingdan Weng, Yuxin Zhang, Keke Dong, Jiangjuan Shao, Shizhong Zheng
BACKGROUND: Traditional Chinese medicine Scutellaria Baicalensis (SB), one of the clinical firstline heat-clearing drugs, has obvious symptomatic advantages for hepatic fibrosis with dampness-heat stasis as its syndrome. We aim to predict and validate the potential mechanism of Scutellaria baicalensis active ingredients against liver fibrosis more scientifically and effectively. METHODS: The underlying mechanism of Scutellaria baicalensis in inhibiting hepatic fibrosis was studied by applying network pharmacology, molecular docking and molecular dynamics simulation...
April 8, 2024: Current Pharmaceutical Design
https://read.qxmd.com/read/38616753/protective-effects-and-mechanisms-of-luteolin-against-acute-respiratory-distress-syndrome-network-pharmacology-and-in-vivo-and-in-vitro-studies
#16
JOURNAL ARTICLE
Quan Li, Juan Chen, Yi Ren, Zhizhou Yang, Mengmeng Wang, Wei Zhang, Liping Cao, Haijun Sun, Shinan Nie, Zhaorui Sun
BACKGROUND: Acute Respiratory Distress Syndrome (ARDS) is an acute life-threatening disease, and luteolin has the potential to become a therapeutic agent for ARDS. However, its mechanism of action has not yet been clarified. OBJECTIVE: The present study explored the potential effects and mechanisms of luteolin in the treatment of ARDS through network pharmacology analysis and verified them through biological experiments. METHODS: The potential targets of luteolin and ARDS were obtained from online databases...
April 8, 2024: Current Pharmaceutical Design
https://read.qxmd.com/read/38584541/recent-advancements-in-refashioning-of-nsaids-and-their-derivatives-as-anticancer-candidates
#17
JOURNAL ARTICLE
Asmaa E Kassab, Ehab M Gedawy
Inflammation is critical to the formation and development of tumors and is closely associated with cancer. Therefore, addressing inflammation and the mediators that contribute to the inflammatory process may be a useful strategy for both cancer prevention and treatment. Tumor predisposition can be attributed to inflammation. It has been demonstrated that NSAIDs can modify the tumor microenvironment by enhancing apoptosis and chemosensitivity and reducing cell migration. There has been a recent rise in interest in drug repositioning or repurposing because the development of innovative medications is expensive, timeconsuming, and presents a considerable obstacle to drug discovery...
April 5, 2024: Current Pharmaceutical Design
https://read.qxmd.com/read/38584540/a-comprehensive-guide-to-the-development-evaluation-and-future-prospects-of-self-nanoemulsifying-drug-delivery-systems-for-poorly-water-soluble-drugs
#18
JOURNAL ARTICLE
Abhishek Chauhan, Raj Kamal, Ritika Mishra, Devank Shekho, Ankit Awasthi
Self-Nano Emulsifying Drug Delivery Systems (SNEDDS) are novel formulations that can enhance the solubility and bioavailability of poorly water-soluble drugs. SNEDDS are composed of lipids, surfactants, co-solvents, and drugs and can spontaneously form nanoemulsions when mixed with water under mild agitation. SNEDDS can be formulated as liquid or solid dosage forms and can improve drug absorption by increasing the interfacial area, protecting the drug from degradation, and facilitating lymphatic transport. SNEDDS is characterized by various parameters such as particle size, zeta potential, droplet morphology, emulsification efficiency, drug solubility, and stability...
April 5, 2024: Current Pharmaceutical Design
https://read.qxmd.com/read/38584554/neuropilin-1-binding-peptide-as-fusion-to-diphtheria-toxin-induces-apoptosis-in-non-small-cell-lung-cancer-cell-line
#19
JOURNAL ARTICLE
Sara Eghtedari, Mahdi Behdani, Fatemeh Kazemi-Lomedasht
BACKGROUND: Targeted cancer therapy can be considered as a new strategy to overcome the side effects of current cancer treatments. Neuropilin-1 (NRP-1) is a transmembrane glycoprotein that is expressed in endothelial cells and tumor vessels to stimulate angiogenesis progression. Targeted diphtheria toxin (DT)- based therapeutics are promising tools for cancer treatment. This study aimed to construct a novel NRP-1 binding peptide (as three repeats) (CRGDK) as a fusion to truncated DT (DTA) (DTA-triCRGDK) for targeted delivery of DT into NRP-1 expressing cells...
April 4, 2024: Current Pharmaceutical Design
https://read.qxmd.com/read/38584553/celastrol-elicits-antitumor-effects-through-inducing-immunogenic-cell-death-and-downregulating-pd-l1-in-ccrcc
#20
JOURNAL ARTICLE
Hong-Fang Li, Neng Zhu, Jia-Jun Wu, Ya-Ning Shi, Jia Gu, Li Qin
BACKGROUND: Targeting immunogenic cell death (ICD) is considered a promising therapeutic strategy for cancer. However, the commonly identified ICD inducers promote the expression of programmed cell death ligand 1 (PD-L1) in tumor cells, thus aiding them to evade the recognition and killing by the immune system. Therefore, the finding of novel ICD inducers to avoid enhanced PD-L1 expression is of vital significance for cancer therapy. Celastrol (CeT), a triterpene isolated from Tripterygium wilfordii Hook...
April 4, 2024: Current Pharmaceutical Design
journal
journal
32445
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.